Skip to main content

Health condition

PTEN hamartoma tumour syndrome

PTEN hamartoma tumour syndrome - including Cowden syndrome - raises lifetime risks of breast, thyroid, endometrial, kidney and bowel tumours, alongside benign overgrowths; a structured surveillance programme addresses each risk in turn.

Why trust this guide

  • 01

    Editorial team

    Written by our editorial team from the UK sources listed on each page.

  • 02

    Sourced from guidance

    Checked against current NHS and UK specialist society guidance at the time of review.

  • 03

    Current for 2026

    Reviewed on 2026-09-27 with the next review scheduled for 2027-09-27.

Key facts

The essentials at a glance.

Which gene and test confirm it, who should be tested in the family, and which specialist to see.

  • Caused by PTEN gene variants; autosomal dominant

  • Clues: macrocephaly, multiple skin papules (trichilemmomas), thyroid nodules and a personal or family pattern of early breast or thyroid cancer

  • Surveillance: annual thyroid ultrasound; enhanced breast screening from 30 for women; endometrial awareness and assessment from around 35; renal imaging from 40; colonoscopy from 35

  • Risk-reducing surgery is discussed individually, particularly for breast risk

Understanding the condition

What it is and what happens next.

What causes it, how it is confirmed, and the testing and specialist routes available in the UK.

What it is and how it presents

PTEN normally restrains cell growth, so its loss produces both the benign - a large head circumference, hamartomatous polyps, skin papules around the nose and mouth - and the malignant, with female breast cancer risk the steepest at up to 60-85% lifetime, and thyroid, endometrial, renal and colorectal cancers each elevated enough to earn their own screening line. Individually the features are common; the combination is what should prompt testing, and macrocephaly is the most underused clue in adult medicine.

Testing, surveillance and specialist care

A confirmed PTEN variant converts vague familial worry into a written surveillance calendar coordinated between genetics, breast services, endocrinology and gastroenterology, and offers relatives a definitive cascade test. Counselling covers the variable expression - many carriers have mainly benign features - and risk-reducing options where they apply. NHS clinical genetics services carry some of the longest waits in the health service, often many months for a first appointment, whereas private genetic testing and a specialist review can typically be arranged within around two weeks.

Seeing a specialist

Who to see, and how quickly you can be seen.

The specialist for this condition is usually a clinical geneticist. Your GP can refer you on the NHS, or you can arrange a private consultation directly.

A quiet reminder

This guide is for information, not medical advice.

Your GP knows your history and can tell you which parts apply to you. If in doubt, see them - and seek urgent care for any emergency symptoms.

Frequently asked

Common questions about PTEN hamartoma tumour syndrome.

Quick, plain-English answers to what people ask us most.

  • What is PTEN hamartoma tumour syndrome?

    PTEN hamartoma tumour syndrome is a group of rare inherited conditions caused by mutations in the PTEN gene, leading to an increased risk of both benign growths (hamartomas) and certain cancers throughout the body.

  • What causes PTEN hamartoma tumour syndrome?

    It's caused by inherited mutations in the PTEN gene, which normally helps regulate cell growth; when this control is lost, it can lead to excessive, sometimes abnormal cell growth in various tissues.

  • What are the symptoms?

    Features vary but can include benign growths in the skin, digestive tract, and other tissues, macrocephaly (larger than average head size), and developmental features in some cases, alongside an increased risk of certain cancers including breast, thyroid, and endometrial cancer.

  • Is PTEN hamartoma tumour syndrome dangerous?

    Yes, the increased cancer risk associated with this condition is significant, making regular, structured cancer surveillance an essential part of long-term management for affected individuals.

  • Is PTEN hamartoma tumour syndrome hereditary?

    Yes, it's inherited in an autosomal dominant pattern, meaning each child of an affected parent has a 50% chance of inheriting the condition.

  • Can PTEN hamartoma tumour syndrome be treated?

    There's no cure for the underlying genetic condition, but regular, structured surveillance for associated cancers allows early detection and treatment, and specific benign growths can be treated or removed if they cause problems.

  • How is PTEN hamartoma tumour syndrome diagnosed?

    Genetic testing confirming a PTEN mutation, often prompted by characteristic clinical features or a family history of the associated cancers, establishes the diagnosis.

  • What surveillance is recommended for PTEN hamartoma tumour syndrome?

    Regular screening typically includes breast, thyroid, and endometrial cancer surveillance for adults, alongside monitoring for other associated features, following specific guidelines developed for this condition.

  • Should family members be tested for PTEN mutations?

    Yes, genetic counselling and testing for close relatives is recommended once a PTEN mutation is confirmed in a family member, as they may also carry the mutation and benefit from similar surveillance.

  • When should I see a specialist, and how quickly can I be seen privately?

    See a genetic specialist if you have relevant features or a family history suggesting this condition. Private genetic assessment is typically available within about two weeks, faster than standard NHS pathways for this rare condition.